Katelyn Byrne

Assistant Professor

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Katelyn Byrne is an Assistant Professor at Oregon Health & Science University in the United States. Her research primarily focuses on immunotherapy and the tumor microenvironment, with recent articles exploring the use of CD40 agonistic monoclonal antibodies in the treatment of pancreatic adenocarcinoma and glioblastoma. She investigates the mechanisms of immune infiltration and the therapeutic implications of immune profiling in various cancers, including those associated with COVID-19.

Articles (8)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Courtney Kureshi

Dana-Farber Cancer Institute

UNITED STATES

View details

Yaroslav Kaminskiy

Northwestern University

UNITED STATES

View details

Lestat Ali

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Katelyn Byrne

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40

Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes

cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes

CCL5 mediates CD40-driven CD4<sup>+</sup>T cell tumor infiltration and immunity

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity

Collaborators (3)

Courtney Kureshi

Yaroslav Kaminskiy

Lestat Ali

Make your next move.